Noxopharm Ltd. (AU:NOX) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Noxopharm Limited has bolstered its cash reserves through a substantial rebate from the Australian Government’s Research and Development Tax Incentive scheme, receiving over $2.3 million. This financial boost supports the company’s innovative work on cancer and inflammation treatments as well as its upcoming HERACLES clinical trial. By repaying a significant loan, Noxopharm is strategically positioned to advance its Chroma™ and Sofra™ technology platforms.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.